2026 Kim N. Chi: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	104	6901	6490	262	249	629	63580

Overview

Kim N. Chi is affiliated with the BC Cancer Agency in Canada and has an extensive research profile focused primarily on medical and oncological sciences. Their work spans multiple related subfields including pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, oncology, cancer research, and molecular biology.

Their research centers on several main topics, most notably prostate cancer treatment and research, radiopharmaceutical chemistry and applications, prostate cancer diagnosis and treatment, PARP inhibition in cancer therapy, multiple myeloma research and treatments, testicular diseases and treatments, and sarcoma diagnosis and treatment.

Frequent collaborators in their research include Fred Saad, Lucia Nappi, Christian Kollmannsberger, Gerhardt Attard, and Neil Fleshner.

Kim N. Chi has published in a variety of journals, with frequent contributions to:

European Urology
Canadian Urological Association Journal
Scientific Reports
Cancer Research
Journal of Clinical Oncology

Key papers authored or co-authored by Kim N. Chi include:

"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer" (2023, Journal of Clinical Oncology)
"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial" (2023, The Lancet Oncology)
"Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)" (2024, Radiology)
"Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors" (2020, European Urology)
"Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the "ideal" patient" (2020, Cancer Medicine)

Best Publications

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

7050
Citations
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

5044
Citations
Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

4966
Citations
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Karim Fizazi;Nam Phuong Tran;Luis Fein;Nobuaki Matsubara

2099
Citations
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

1787
Citations
Olaparib for metastatic castration-resistant prostate cancer

Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

1765
Citations
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

1528
Citations
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

1372
Citations
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Stephen Begbie

1270
Citations
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Kim N. Chi;Neeraj Agarwal;Anders Bjartell;Byung Ha Chung

1222
Citations
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

1198
Citations
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi;Nam Phuong Tran;Luis Fein;Nobuaki Matsubara

680
Citations
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

David A. Quigley;Ha X. Dang;Shuang G. Zhao;Paul Lloyd

651
Citations
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Rahul Aggarwal;Jiaoti Huang;Joshi J. Alumkal;Li Zhang

645
Citations
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

595
Citations
Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer

Arun A Azad;Stanislav V Volik;Alexander W Wyatt;Anne Haegert

500
Citations
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala;Matti Annala;Gillian Vandekerkhove;Daniel Khalaf;Sinja Taavitsainen

458
Citations
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

417
Citations
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

Alexander W Wyatt;Matti Annala;Rahul Aggarwal;Kevin Beja

389
Citations
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

K.L. Noonan;S. North;R.L. Bitting;A.J. Armstrong

384
Citations

Frequent Co-Authors

Martin E. Gleave University of British Columbia

Alexander W. Wyatt University of British Columbia

Fred Saad University of Montreal

Karim Fizazi University of Paris-Saclay

Eric J. Small University of California, San Francisco

Tomasz M. Beer Oregon Health & Science University

Johann S. de Bono Institute of Cancer Research

Howard I. Scher Memorial Sloan Kettering Cancer Center

Cora N. Sternberg Cornell University

Celestia S. Higano University of Washington

External Links

Personal website of Kim N. Chi

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring alternative pathways in the healthcare field can provide flexible and practical options for aspiring professionals. Online degrees are increasingly popular for those managing work, family, or other commitments alongside their studies.

Advanced nursing degrees, like the most affordable dnp programs, allow registered nurses to gain the skills necessary for leadership, education, and executive roles. Similarly, a online pharmd programs offers a flexible route for professionals aiming to become licensed pharmacists, combining rigorous curriculum with the convenience of online learning.

Beyond direct patient care roles, there is significant demand in health data management. HIM programs prepare students to manage patient records, ensure security, and lead healthcare IT systems.

For those interested in the business and administrative side of medicine, short-term medical billing and coding cost courses make it possible to quickly enter the workforce or supplement your existing healthcare career.